CFO transition
Vertex Pharmaceuticals Incorporated CFO transition: Jonathan Poole to succeed Charles F. Wagner, Jr.
Vertex Pharmaceuticals Incorporated reported in a Form 8-K filed September 1, 2026 that Jonathan Poole will succeed Charles F. Wagner, Jr. as Executive Vice President and Chief Financial Officer, effective January 1, 2027.
In the filing's words
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Vertex Pharmaceuticals Incorporated (VRTX) |
|---|---|
| Event | Transition |
| Incoming | Jonathan Poole |
| Outgoing | Charles F. Wagner, Jr. |
| Title in the filing | Executive Vice President and Chief Financial Officer |
| Effective | January 1, 2027 |
| 8-K filed | September 1, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Senior Vice President, Finance, Vertex Pharmaceuticals Incorporated |
| SEC CIK | 0000875320 |
Vertex Pharmaceuticals Incorporated reported this change in a Form 8-K, Item 5.02, filed September 1, 2026. The filing's own words are quoted above.
Other records naming Charles F. Wagner, Jr.
1The outgoing officer on this record, matched by name. Career line.
2026-02-13 · 10-K signature
Charles F. Wagner, Jr. signed Vertex Pharmaceuticals's annual report as Executive Vice President and Chief Operating & Financial Officer (Principal Financial Officer)
Same industry, September 2026
5Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
6 weeks ago· 2026-09-30DeparturePTPI
Petros Pharmaceuticals, Inc. discloses CFO departure: Robert Weinstein
6 weeks ago· 2026-09-28InterimGANX
Gain Therapeutics, Inc. names Gene Mack interim CFO
2 months ago· 2026-09-11InterimRNAZ
TransCode Therapeutics, Inc. names John Tattory interim CFO
2 months ago· 2026-09-08TransitionKURA
Kura Oncology, Inc. CFO transition: Jennifer Fulk to succeed Troy E. Wilson, Ph.D., J.D.
2 months ago· 2026-09-03AppointmentLBRX
LB Pharmaceuticals Inc appoints Joseph M. Miller as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Jonathan Poole? Send a correction with the primary source.